Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease

Abstract

In a slowly progressive disorder like Alzheimer disease, evaluation of the clinical effect of novel drug candidates requires large numbers of patients and extended treatment periods. Current cell- and animal-based disease models of Alzheimer disease are poor at predicting a positive treatment response in patients. To help bridge the gap between disease models and large and costly clinical trials with high failure rates, biomarkers for the intended biochemical drug effect may be of value. Such biomarkers may be called 'theragnostic'. Here, we review the literature addressing the prospective value of these biomarkers.

Background

Three decades of multidisciplinary research have resulted in detailed knowledge of the molecular pathogenesis of Alzheimer disease (AD) [1]. We know that the symptoms of AD are caused by synaptic dysfunction and neuronal death in the areas of the brain that are involved in memory consolidation and other cognitive functions [1]. This neurodegeneration is firmly associated with aggregation of the 40- to 42-amino acid amyloid beta (Aβ) peptide into senile plaques, phosphorylation and aggregation of tau proteins that form neurofibrillary tangles, and microglial activation that may be a protective response or contribute to the neuronal dysfunction and damage [2]. The relative importance of these processes to the clinical presentation of the disease remains uncertain.

Clinical trials of novel anti-AD drugs face at least two major challenges. First, the new types of drug candidates that attack basic disease processes are likely to be most effective in early stages of the disease, before neuronal degeneration has become too widespread and severe [3]. However, clinical methods that recognize early AD are lacking. Second, the drug candidates may slow down the degenerative process without having any immediate and easily recognizable symptomatic effect [4]. This makes evaluation of the drug effect difficult. Theragnostic biomarkers (that is, biomarkers that detect and monitor biochemical effects of the drug) may help solve some of these problems. Here, we review three pathological processes that are thought to be involved in the complex surge of AD - namely the amyloid cascade, abnormal tau phosphorylation, and microglial activation with neuroinflammation - and the currently available biomarkers thought to reflect them (Figure 1).

Figure 1

Summary of candidate theragnostic biomarkers that reflect key drug targets in the Alzheimer disease (AD) process. Beta-secretase inhibitors should reduce cerebrospinal fluid (CSF) levels of amyloid beta (Aβ) isoforms starting at the first amino acid in the Aβ sequence (Aβ1-X). Gamma-secretase inhibitors should reduce Aβ1-40 and Aβ1-42 and increase Aβ1-14, Aβ1-15, and Aβ1-16. Both Aβ immunotherapy and anti-aggregation agents might be monitored by CSF levels of Aβ1-40 and Aβ1-42. Therapy-induced Aβ degradation might be monitored by CSF levels of different Aβ peptides, depending on the proteolytic pathway used for degradation. Aβ efflux from the brain to the blood might be monitored by measurement of Aβ in CSF and plasma. Inflammatory markers in plasma and CSF as well as CSF levels of CCL2 and chitotriosidase activity are putative markers of microglial activity and may change in response to treatments that influence microglial activity. Treatment with tau hyperphosphorylation inhibitors might be monitored with CSF phospho-tau (P-tau) levels. Downstream effects on axonal degeneration from disease-modifying treatments could be monitored by using the axonal damage markers CSF total tau (T-tau) and neurofilament light protein (NFL).

Core biomarkers of Alzheimer disease

It is well established that cerebrospinal fluid (CSF) levels of total tau (T-tau), phospho-tau (P-tau), and the 42-amino acid fragment of Aβ (Aβ42) reflect core elements of the AD process [3]. T-tau is a marker of cortical axonal degeneration and disease activity [5–7]. P-tau reflects neurofibrillary pathology [8, 9]. Aβ42 is a marker of plaque pathology [9–12]. Together, these biomarkers identify AD and predict AD in mild cognitive impairment (MCI) with a sensitivity and specificity of 75% to 95% [3]. The predictive power is, however, sub optimal in general populations as compared with MCI cohorts because of the lower prevalence of incipient AD in this group [13]. Plasma biomarkers reflective of pathophysiological changes in the AD brain are highly warranted, the subject of intense research, but unfortunately still lacking [3].

Drug targets

Amyloid

Experimental data, as well as longitudinal studies in humans, suggest that certain forms of Aβ may act as initiators in the disease process with potent toxic effects at the synaptic level [2]. Based on this knowledge, novel treatments aimed at inhibiting Aβ toxicity have been developed and are being tested in patients [14]. These include secretase inhibitors and modulators that affect the production of Aβ from amyloid precursor protein (APP), immunotherapy aimed at increasing the clearance of Aβ from the brain, and Aβ aggregation inhibitors that should prevent pathological build-up of the peptide in the brain [14].

Tau

Among the typical brain lesions in AD are neurofibrillary tangles that consist of abnormally phosphorylated forms of the microtubule-stabilizing protein tau [15]. Tau expression is high in non-myelinated cortical axons, especially in the regions of the brain (such as the limbic cortex, including the hippocampus) which are involved in memory consolidation [16]. Hyperphosphorylation of tau causes the protein to detach from the microtubules and destabilizes the axons [17]. This process promotes axonal and synaptic plasticity in the developing brain [17] but may be pathological in the adult brain and specifically related to a group of disorders referred to as tauopathies; this group includes AD and some forms of frontotemporal dementia [15]. Inhibiting tau phosphorylation or aggregation has been considered a promising strategy to slow down the neurodegeneration in AD. Drug candidates intervening in tau-related disease processes (for example, inhibitors of the tau kinase GSK3β and tau aggregation inhibitors) exist but are still in an early phase of development [14].

Microglial activation

Microglia are the resident immune cells of the central nervous system (CNS) [18] and are macrophages of myeloid lineage and invade the CNS during embryogenesis. These innate immune cells perform the majority of the immunological surveillance in the CNS. However, in certain conditions such as multiple sclerosis or neuroborreliosis, infiltration of T cells but also B cells into the CNS occurs. Microglia are usually in a resting state but at any time may become activated in response to infection or injury [18]. The key question of microglia in AD is whether the inflammation mediated via microglia is beneficial or not. The capability of microglia to release reactive oxygen species, nitric oxide, interleukin-1-beta (IL-1β), and tumor necrosis factor-alpha (TNFα) is beneficial in response to invading pathogens. However, these compounds are also neurotoxic and collateral damage to neurons is frequent during infections. The same may occur in AD because plaques function as immunological triggers for the activation and recruitment of microglia, which may result in neuron loss [19]. On the other hand, microglia have been shown to clear deposits of Aβ through the Toll-like receptor 4 (TLR4), and AD mice with a defective TLR4 have increased deposits of Aβ [20].

Other drug targets

Besides the three targets mentioned above, several other approaches are aimed at improving neural transmission and memory consolidation in AD. These include nerve growth factor gene therapy, stimulation of nicotinergic acetylcholine receptors by varenicline, protein kinase C activation by bryostatin 1, and many more [21]. Theragnostic biomarkers for each of these drugs may be different from those reviewed below and are specifically related to the mode of action of the drug.

Theragnostic biomarkers

General issues

Theragnostic markers have accelerated the development of treatments in some types of cancer, HIV infection, atherosclerosis, and multiple sclerosis, and cancer specific fusion transcripts or mutations, viral load, plasma levels of low-density lipoprotein cholesterol, and brain MRI (magnetic resonance imaging) white matter lesion burden, respectively, have been used to ascertain that the drug candidate is beneficial [22]. These examples indicate that theragnostic markers may be useful in evaluating novel therapeutics also in AD. Furthermore, such studies may help to bridge the gap between animal studies that are poor at predicting treatment success in humans and large clinical trials [1]. Sometimes, these types of bio markers are referred to as surrogate markers of pathogenic processes. However, the term surrogate marker often indicates a marker that is (i) a validated substitute for a clinically meaningful endpoint and (ii) expected to predict the effect of therapy [23, 24]. This definition goes beyond a mere correlation between a laboratory measurement and a clinical outcome or a pathogenic process since a fully validated surrogate marker also requires proof that intervention on the surrogate marker predicts the effect on the clinical outcome [25]. If applied in full by regulatory authorities, very few biomarkers in medicine live up to these requirements, which may obstruct implementation of surrogate biomarkers in large-scale clinical trials. However, this circumstance does not hinder the use of non-validated surrogate markers when deciding upon the most promising drug candidates in early stages of drug development. Rather, this approach is advocated by the US Food and Drug Administration [26].

Are they useful?

To date, only preliminary reports suggest that CSF biomarkers may be useful in detecting and monitoring biochemical effects of novel drugs against AD. With regard to biomarkers for amyloid pathology, the many factors that influence steady-state levels of Aβ in CSF (production, aggregation, enzymatic clearance, and bidirectional transport across the blood-brain barrier) make it difficult to predict what different amyloidtargeting treatment paradigms might do to CSF Aβ concentrations. In fact, any treatment-induced change to an amyloid-related biomarker which is informative with respect to clinical outcome would be a major step forward. So far, data from animal studies show that γ- secretase inhibitor treatment results in a reduction in cortical, CSF, and plasma levels of Aβ [27, 28]. Similarly, treatment of monkeys with a BACE1 inhibitor reduced the CSF levels of Aβ42, Aβ40, and β-sAPP [29]. Other promising biomarkers that are closely linked to the amyloidogenic process in AD are CSF BACE1 (the major β-secretase) concentration and activity, CSF levels of α- and β-cleaved soluble APP, and Aβ oligomers [30–32]. These biomarkers appear to provide information of limited diagnostic usefulness but may turn out to be important for identifying treatment effects of drugs that are meant to inhibit β-secretase or break up amyloid aggregates.

In patients with AD, it is uncertain how CSF Aβ42 may respond to treatment with efficacious anti-Aβ drugs. A phase IIa study of the Aβ clearance-enhancing compound PBT2 showed a significant dose-dependent reduction in CSF Aβ42 levels during treatment [33]. Data from a clinical study on the amyloid-targeting drug phenserine also showed changes in CSF Aβ levels in response to treatment [34]. However, in the interrupted phase IIa AN1792 trial of active immunization against Aβ, no significant treatment effect on CSF Aβ42 was found [35]. A clinical study on γ-secretase inhibitor treatment also failed to detect any effect on CSF Aβ42 levels [36]. Nevertheless, when the effect of this drug on Aβ production rate by the use of a stable isotope-labeling kinetic technique was evaluated, a clear inhibitory effect of γ-secretase inhibition on Aβ production was identified [37]. Recent data show that shorter Aβ peptides in CSF - namely Aβ1-14, Aβ1-15, and Aβ1-16 - represent a novel APP-processing pathway [38] that is upregulated in a dose-dependent manner in response to γ-secretase inhibition [39].

Given longitudinal studies of conditions involving acute neuronal injury [40] and data from the interrupted phase IIa AN1792 trial [35], T-tau should decrease toward normal levels if a treatment is successful in inhibiting the neurodegenerative process in AD. The same may be expected for P-tau, as suggested by two recent pilot studies on memantine [41, 42].

Currently, there are no established CSF biomarkers for microglial activation which could be used as theragnostic markers in trials aimed at inhibiting, boosting, or modulating microglial activity in AD. Chemokine (C-C motif) ligand 2 (CCL2) (also called monocyte chemoattractant protein-1, or MCP-1) and chitotriosidase are firmly associated with macrophage activation in the periphery [43, 44] and may be considered promising markers of microglial activation in the CNS, but studies in relation to AD are scarce [45]. However, several biomarkers for general inflammation exist. Pilot studies showed increased CSF levels of transforming growth factor-beta (TGFβ) in AD as compared with controls [46, 47]; this result was recently confirmed in a meta-analysis of cytokines in AD [48]. Other classical markers such as IL-1β, IL-6, and TNFα were not altered in the CSF of patients with AD. The plasma levels of several cytokines such as IL-1β, IL-6, IL-12, IL-18, TNFα, and TGFβ- but not IL-4, IL-8, IL-10, interferon-γ, or C-reactive protein - were increased in AD. Together, these data argue for an inflammatory component in AD. However, the results of anti-inflammatory therapy in AD have been contradictory [49]. As explained above, the link between inflammation and other core disease processes in AD remains elusive.

Concluding remarks

Theoretical reasoning suggests that theragnostic biomarkers could play a major role in drug development against AD, but, admittedly, the body of literature supporting this view is limited at present. We know quite a lot about central pathogenic features of the disease, and several biomarkers that monitor these features exist. A number of phase 0-I clinical trials indicating small but statistically significant effects on theragnostic biomarkers, mostly in relation to axonal integrity and amyloid pathology, have been published. Interpreting these biomarker results is, however, complicated by the fact that none of the studies was designed to detect clinical effects. This circumstance precludes analyses of whether the patients with biomarker changes imposed by the treatment were those with the clearest clinical benefit.

The recent interruption of the phase III trials (IDENTITY [Interrupting Alzheimer's Dementia by Evaluating Treatment of Amyloid Pathology] and IDENTITY-2) of the γ-secretase inhibitor semagacestat (LY450139) (Eli Lilly and Company, Indianapolis, IN, USA) may be considered a blow to the field of theragnostic biomarkers. Despite compelling evidence in cell and animal models, as well as plasma Aβ data [36] and Aβ turnover rates [37] in humans, suggesting that the compound reduces Aβ production, cognition declined faster in the treatment arms compared with placebo. In our view, these data should spur us to continue developing more biomarkers for APP- and Aβ- processing for other desired drug effects such as improvement of neural transmission as well as for undesired effects (for example, inhibition of Notch signaling). For another recently failed trial (tarenflurbil, which is supposed to act as a γ-secretase modulator), there were plenty of bio marker data suggesting that the drug did not hit its target in the human brain [50]. These data could have curbed the enthusiasm to move to phase III and thus saved a lot of money.

Several other clinical trials on disease-modifying drug candidates which include biomarkers as readouts are currently ongoing. These trials will provide more evidence on whether biomarkers will be useful as tools to select the most promising drug candidates for phase II/III trials for AD.